Rock BioMedical, Inc.
- Biotech or pharma, therapeutic R&D
Rock BioMedical is a glycoengineering company harnessing the power of glycan modulation to develop better vaccines and antibody drugs. Glycosylation—complex and often overlooked—plays a key role in immunity, cancer, and autoimmune diseases. Our proprietary low-sugar vaccine platform, named a 2023 IUPAC Top 10 Emerging Technology, enhances immune responses by exposing conserved viral epitopes. We also engineer therapeutic antibodies with optimized glycan profiles to improve efficacy and durability. With a team in Taipei and Boston, Rock Bio is advancing a low-sugar universal vaccine against COVID in Phase I and developing mRNA vaccines and glyco-optimized biobetters. Positioned at the forefront of glycoengineering innovation, we aim to transform disease prevention and treatment.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}